Next-Generation DNA Editing
Powered by Cas-Free, Innate Enzyme DNA Editing.
The Next Generation of DNA editing tech.
Our RIDE™ platform harnesses innate human enzymes, completely eliminating the need for bacterial Cas proteins. It delivers unprecedented precision with lifelong redosability.
How RIDE™ Works
Our RNA-based guide system intentionally creates a structural mismatch, acting as a beacon to recruit your body's own innate enzymes. This enables us to safely and flawlessly repair DNA sequences.
1. Design
We engineer a highly specific Guide RNA. At its tail, we design a specialized secondary structure—a "decoy"—that acts as a powerful beacon to lure and recruit innate human repair enzymes natively present in the cell.
2. Binding & Recruitment
Our Guard-RNA invades the double-stranded DNA at the target sequence. The resulting mismatch structure acts as a powerful metabolic beacon, successfully recruiting native, innate human DNA repair enzymes to the precise mutation site.
3. Seamless Restoration
The activated endogenous enzyme uses the RNA strand as a pristine template, smoothly correcting the biological error and rewriting the DNA.
Unprecedented Safety
Zero Off-Target Risks
Expanding the Horizon of Cures.
Expanding the boundaries of precision medicine across a diverse range of genetic disorders and oncogenic targets.
CFTR Target
Cystic Fibrosis (CF). The G551D mutation impairs chloride channel function.
Validated mutation: G551D
SERPINA1 Target
Alpha-1 Antitrypsin Deficiency. The E366K mutation leads to compromised lung/liver function.
Validated mutation: E366K
GJB2 Target
Non-syndromic Hearing Loss (DFNB1). R143W affects the connexin 26 gap junction protein.
Validated mutation: R143W
RNH2B Target
Aicardi-Goutières Syndrome (AGS). The A177T mutation drives severe auto-inflammatory neurodegeneration.
Validated mutation: A177T
IDS Target
Hunter Syndrome (MPS II). R468Q is a severe mutation impeding mucopolysaccharide breakdown.
Validated mutation: R468Q
KRAS Target
Pancreatic/Colorectal Cancer. G12 and G13 are classic oncogenic driver mutations.
Validated mutations: G12, G13
PIK3CA Target
Breast and solid tumors. H1047R hyperactivates the PI3K signaling pathway.
Validated mutation: H1047R
GRIK2 Target
Neurodevelopmental Disorders (e.g., Autism spectrum/Intellectual disability). Target mutation A490V.
Validated mutation: A490V
ZNF292 Target
Intellectual Disability / Neurodevelopmental delay. Target mutation H1542R.
Validated mutation: H1542R
P53 Target
Universal Tumor Suppressor. R175H and R248Q are among the most common hot-spot mutations in human cancers.
Validated mutations: R175H, R248Q
The 'Gene Rewind' Era.
" Going beyond merely treating disease, we completely restore somatic mutations—accumulated through aging and stress, such asTP53andTP53 Mutation
Universal Tumor Suppressor. R175H and R248Q are among the most common hot-spot mutations in human cancers.
JAK2—back to their original healthy sequences. We are leading the realization of genetic age-reversal. "JAK2 Mutation
Associated with myeloproliferative neoplasms (blood cancers). The V617F mutation drives abnormal blood cell production.
GERNA Biotech R&D